In clear cell renal cell carcinoma (ccRCC), SREBP2 interacts with MED15 that acts as a SREBP2 coactivator to promote cholesterol biosynthesis enzyme expression, resulting in enhancing malignant tumor behavior phenotypes (Hua et al., 2024). This evidence concerns the gene MED15 and nonpapillary renal cell carcinoma.